Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
5
×
boston blog main
boston top stories
5
×
clinical trials
life sciences
national blog main
national top stories
5
×
new york blog main
san francisco blog main
atlas venture
deals
gene therapy
regeneron pharmaceuticals
rna interference
san diego blog main
san francisco top stories
startups
adeno-associated virus
akcea therapeutics
alexion pharmaceuticals
allosteric
alnylam pharmaceutials
alnylam pharmaceuticals
arrowhead pharmaceuticals
astellas pharma
atopic dermatitis
audentes therapeutics
autoimmune disorders
avidity biosciences
barry greene
bluebird bio
boehringer ingelheim
boston university
brace pharma
cancer
chemotherapy
cisplatin
cleva pharma
dan ollendorf
What
ago
5
×
medicines
therapeutics
long
rna
years
abandoning
adding
address
adds
aiming
allosteric
alnylam
approve
awaits
baggage
balance
biological
biotechs
build
clinic
companies
considering
crossed
cuts
data
deal
decades
decibel
decision
development
dicerna
discovered
disease
diseases
drug
drugs
dyne
early
elusive
Language
unset
Current search:
ago
×
" national top stories "
×
" boston top stories "
×
boston
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision